

Sent: Tue 4/13/2021 6:55:36 PM

Subject: RE: SENSITIVE - Information meeting 06.04.2021 15:00-16:00 -Molnupiravir

Received: Tue 4/13/2021 6:55:39 PM

SENSITIVE*: Limited Joint Procurement of medical countermeasures

Dear Members of the Specific Procurement Procedure Steering Committee for monoclonal antibodies,

Following the information meeting on Molnupiravir, we uploaded the slides received from MSD on CIRCABC (<u>Library -> Info</u> meetings)

Please see below information from MSD in response to the question on metabolism asked during the meeting: "Molnupiravir is thought to be metabolized by esterases in plasma or in cells. Molnupiravir does not inhibit or induce any major enzymes (ie P450). Given the limitations of the safety database at the time the clinical development program was initiated, patients with HBV or HCV infection that also have cirrhosis, end-stage liver disease, hepatocellular carcinoma, or an elevated AST or ALT >3 X ULN at screening were excluded."

Kind regards,

SANTE Joint Procurement Agreement Team



European Commission | Health and Food Safety | Public Health | Health Security

LU-2920 Luxembourg | HTC

5.1.2e @ec.europa.eu

^{*} Not for distribution. Do not read or carry openly in public places. Must be stored securely and encrypted in storage and transmission. Destroy copies by shredding or secure deletion. Full handling instructions: https://europa.eu/ldb43PX



